A. Aylott

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2

B. Wynne, J. Llibre, R. van Solingen-Ristea, 2022, Journal of acquired immune deficiency syndromes.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

S. Walmsley, C. Orrell, Kimberly Smith, 2017, The lancet. HIV.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Carbohydrate residues in non-malignant prostatic epithelium as revealed by lectins

P. Abel, G. Williams, C. Marsh, 2004, Urological Research.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Comparison of weight, depth, and diagnostic adequacy of specimens obtained with 16 different biopsy forceps designed for upper gastrointestinal endoscopy.

P. Cotton, B. Danesh, A. Aylott, 1985, Gut.

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

F. Raffi, L. Curtis, B. Wynne, 2014, HIV clinical trials.

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

B. Wynne, R. Mehta, H. Crauwels, 2023, British journal of clinical pharmacology.